Received: 19 January 2022
Accepted: 1 February 2022
First Online: 12 April 2022
: The ethical approval to conduct the pilot survey, pre-test and main survey was granted by the Ethics Committee of China Pharmaceutical University (Project Number: CPU2019015). All methods of the study were carried out in accordance with the ethical standards of the Ethics Committee of China Pharmaceutical University and the principles of CFDA-GCP and the Helsinki Declaration.Written informed consent to participate was signed by all participated.
: Not applicable.
: The authors declare that they have no competing interests.